Welcome to our dedicated page for Avalo Therapeutics SEC filings (Ticker: AVTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Avalo Therapeutics, Inc. filings document clinical, financial, capital-structure, and governance disclosures for a biotechnology issuer developing IL-1β-based therapies. Recent 8-K reports cover abdakibart LOTUS trial materials in hidradenitis suppurativa, operating and financial results, investor presentation updates, and material agreements related to milestone obligations from the AlmataBio acquisition.
The company's proxy materials describe shareholder voting matters, board composition, executive compensation, equity awards, and governance practices. Avalo's filing record also includes disclosure categories tied to common stock and pre-funded warrant financing, Nasdaq inducement awards, risk and operating updates, and formal reporting of material events affecting its clinical-stage business.
T. Rowe Price Investment Management, Inc. filed an amended ownership report for Avalo Therapeutics Inc. common stock. The firm reports beneficial ownership of 3,670 shares, representing 0.0% of the class, all with sole voting and dispositive power. It states that this filing should not be construed as an admission that it is the beneficial owner of these securities and expressly denies such beneficial ownership.
Avalo Therapeutics, Inc. received an amended Schedule 13G filing indicating that Avoro Capital Advisors LLC and Behzad Aghazadeh collectively report beneficial ownership of 2,333,333 shares of Avalo common stock. This represents 4.44% of the outstanding common stock, based on 52,565,572 shares outstanding as of May 8, 2026. The reporting persons each have sole voting and sole dispositive power over these shares and no shared voting or shared dispositive power. The stake is held for investment purposes on behalf of Avoro Life Sciences Fund LLC, and the filers state that the filing should not be construed as an admission of beneficial ownership for all purposes.
Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin report beneficial ownership of 3,610,000 shares of Avalo Therapeutics, Inc. common stock, representing 6.87% of the class as of June 30, 2026.
The reporting persons have shared voting and dispositive power over all 3,610,000 shares and no sole voting or dispositive power. The ownership percentage is based on 52,565,572 shares outstanding as of May 8, 2026, as disclosed by Avalo. David Kroin may be considered a control person of Deep Track Capital, LP, and the parties have agreed to a joint filing.
Avalo Therapeutics, Inc. is reported to have 2,900,000 shares of its common stock beneficially owned through Affinity Healthcare Fund, LP, with investment decisions made by Affinity Asset Advisors, LLC and its managing member, Michael Cho. As of June 30, 2026, these reporting persons held approximately 5.5% of Avalo’s outstanding common stock, based on 52,900,692 shares outstanding. They report sole voting and dispositive power over all 2,900,000 shares and no shared voting or dispositive power.
Avalo Therapeutics, Inc. Chief Strategy Officer Jennifer Riley reported a sale of 2,655 shares of common stock on August 11, 2026. The shares were sold at a weighted average price of $19.5903 per share, in multiple transactions priced between $19.54 and $19.65. Following this sale, Riley directly holds 37,041 shares of Avalo Therapeutics common stock.
Avalo Therapeutics, Inc. Chief Medical Officer Mittie Doyle reported an option exercise and same-day share sale. On August 10, 2026, Doyle exercised a stock option for 679 shares of common stock at $8.04 per share, then sold 679 shares of common stock at $20.00 per share in a separate transaction. The filing states these transactions were effected under a Rule 10b5-1 trading plan adopted on November 13, 2025. Following the option exercise, Doyle had 114,413 stock options remaining under this award.
Avalo Therapeutics (symbol AVTX) has filed a notice of proposed resale of 2,655 shares of common stock. The shares are to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services, with trading routed on NASDAQ on or after August 11, 2026.
The shares were originally acquired on December 10, 2025 through an Employee Stock Purchase Plan for cash consideration.
Avalo Therapeutics, Inc. (AVTX) reports that an affiliate, Morgan Stanley Smith Barney LLC Executive Financial Services, intends to sell common stock on behalf of a party identified in the notice. The planned transaction covers 679 shares of common stock in connection with an exercise of stock options for cash on 08/10/2026.
The notice also lists prior common stock sales for Mittie Doyle under a Rule 10b5-1 trading plan over the past three months, including transactions on 05/15/2026, 05/28/2026, 06/23/2026, 06/30/2026, and 07/27/2026 with share counts ranging from 679 to 4,654 shares.
FMR LLC filed an amended Schedule 13G reporting beneficial ownership of 5,737,966 shares of Avalo Therapeutics, Inc. common stock, representing 10.8% of the class. FMR LLC has sole dispositive power over all reported shares and sole voting power over 5,737,946 shares.
Abigail P. Johnson is also reported as a beneficial owner of the same 5,737,966 shares, with sole dispositive power and no voting power. One or more other persons have rights to receive dividends or sale proceeds from these shares, but no single such person has more than five percent of the total outstanding common stock. Subsidiaries that acquired the securities are identified in an attached Exhibit 99.
State Street Corporation filed a Schedule 13G reporting beneficial ownership of common stock of Avalo Therapeutics, Inc. State Street reports beneficial ownership of 2,889,287 shares of Avalo common stock, representing 5.5% of the class.
State Street reports 0 shares with sole voting and dispositive power and 2,837,724 shares with shared voting power, as well as 2,889,287 shares with shared dispositive power. Subsidiaries involved include SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, and State Street Global Advisors Trust Company.